Thoracic Cancer最新文献

USP22 promotes gefitinib resistance and inhibits ferroptosis in non-small cell lung cancer by deubiquitination of MDM2. USP22 通过去泛素化 MDM2 促进非小细胞肺癌的吉非替尼耐药性并抑制铁变态反应。

IF 2.3 3区医学

Thoracic Cancer Pub Date : 2024-09-24 DOI: 10.1111/1759-7714.15439

Peng Lu, Zhaoguo Li, Hang Xu

{"title":"USP22 promotes gefitinib resistance and inhibits ferroptosis in non-small cell lung cancer by deubiquitination of MDM2.","authors":"Peng Lu, Zhaoguo Li, Hang Xu","doi":"10.1111/1759-7714.15439","DOIUrl":"https://doi.org/10.1111/1759-7714.15439","url":null,"abstract":"Background: The emergence of chemoresistance markedly compromised the treatment efficiency of human cancer, including non-small cell lung cancer (NSCLC). In the present study, we aimed to explore the effects of ubiquitin-specific peptidase 22 (USP22) and murine double minute 2 (MDM2) in gefitinib resistance in NSCLC.Methods: Immunohistochemistry (IHC) assay, quantitative real-time polymerase chain reaction (qRT-PCR) assay and western blot assay were carried out to determine the expression of USP22 and MDM2. Transwell assay and flow cytometry analysis were performed to evaluate cell migration and apoptosis. Cell Counting Kit-8 (CCK-8) assay was employed to assess gefitinib resistance. The phenomenon of ferroptosis was estimated by related commercial kits. The oxidized C11-BODIPY fluorescence intensity by C11-BODIPY staining. The relation between USP22 and MDM2 was analyzed by ubiquitination assay and co-immunoprecipitation (Co-IP) assay.Results: USP22 was abnormally upregulated in NSCLC tissues and cells, and USP22 silencing markedly repressed NSCLC cell migration and facilitated apoptosis and ferroptosis. Moreover, our results indicated that ferroptosis could enhance the suppressive effect of gefitinib on NSCLC cells. Besides, USP22 overexpression enhanced gefitinib resistance and ferroptosis protection in NSCLC cells. Mechanically, USP22 stabilized MDM2 and regulated MDM2 expression through deubiquitination of MDM2. MDM2 deficiency partially restored the effects of USP22 on gefitinib resistance and ferroptosis in NSCLC cells. Of note, we validated the promotional effect of USP22 on gefitinib resistance in NSCLC in vivo through establishing the murine xenograft model.Conclusion: USP22/MDM2 promoted gefitinib resistance and inhibited ferroptosis in NSCLC, which might offer a novel strategy for overcoming gefitinib resistance in NSCLC.","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142308597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of sarcopenia on the prognosis of patients with advanced non-small cell lung cancer treated with antiangiogenic therapy: A propensity score matching analysis. 肌肉疏松症对接受抗血管生成治疗的晚期非小细胞肺癌患者预后的影响：倾向得分匹配分析

IF 2.3 3区医学

Thoracic Cancer Pub Date : 2024-09-22 DOI: 10.1111/1759-7714.15443

Fuchun Huang, Mingxuan Ma, Liye Lang, Shuang Yang, Hui Zhao, Jialin Zhang, Hua Liu

{"title":"Impact of sarcopenia on the prognosis of patients with advanced non-small cell lung cancer treated with antiangiogenic therapy: A propensity score matching analysis.","authors":"Fuchun Huang, Mingxuan Ma, Liye Lang, Shuang Yang, Hui Zhao, Jialin Zhang, Hua Liu","doi":"10.1111/1759-7714.15443","DOIUrl":"https://doi.org/10.1111/1759-7714.15443","url":null,"abstract":"Background: Limited information is available regarding the impact of sarcopenia on the prognosis of antiangiogenic therapy in individuals with advanced non-small cell lung cancer (NSCLC). This study primarily sought to examine the prognostic significance of sarcopenia in individuals with advanced NSCLC undergoing antiangiogenic therapy.Methods: We retrospectively enrolled all patients who met the inclusion and exclusion criteria from 2019 to 2021 at Nantong University Hospital. Patients were grouped according to the presence or absence of sarcopenia. After propensity score matching (PSM), progression-free survival (PFS), overall survival (OS), and adverse event rates were compared between the two groups. Factors associated with prognosis were screened using univariate and multivariate analyses.Results: A total of 267 patients were included, with a total of 201 matched at baseline after PSM (77 in the sarcopenia group and 124 in the non-sarcopenia group). The sarcopenia group had lower PFS (p = 0.043) and OS (p = 0.011) than the non-sarcopenia group and a higher incidence of adverse events (p = 0.044). Multivariate analysis suggested that sarcopenia is an independent prognostic risk factor for OS in advanced NSCLC patients receiving antiangiogenic therapies (p = 0.009). Results of subgroup analyses showed some differences in the impact of sarcopenia on survival prognosis in populations with different characteristics.Conclusion: Patients with advanced NSCLC with comorbid sarcopenia exhibit a worse prognosis when treated with antiangiogenic therapy, and preventing and ameliorating sarcopenia may lead to better survival outcomes in patients with advanced NSCLC.","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142296458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Application of machine learning for the differentiation of thymomas and thymic cysts using deep transfer learning: A multi-center comparison of diagnostic performance based on different dimensional models. 利用深度迁移学习将机器学习用于区分胸腺瘤和胸腺囊肿：基于不同维度模型的多中心诊断性能比较。

IF 2.3 3区医学

Thoracic Cancer Pub Date : 2024-09-20 DOI: 10.1111/1759-7714.15454

Yuhua Yang, Jia Cheng, Liang Chen, Can Cui, Shaoqiang Liu, Minjing Zuo

{"title":"Application of machine learning for the differentiation of thymomas and thymic cysts using deep transfer learning: A multi-center comparison of diagnostic performance based on different dimensional models.","authors":"Yuhua Yang, Jia Cheng, Liang Chen, Can Cui, Shaoqiang Liu, Minjing Zuo","doi":"10.1111/1759-7714.15454","DOIUrl":"https://doi.org/10.1111/1759-7714.15454","url":null,"abstract":"Objective: This study aimed to evaluate the feasibility and performance of deep transfer learning (DTL) networks with different types and dimensions in differentiating thymomas from thymic cysts in a retrospective cohort.Materials and methods: Based on chest-enhanced computed tomography (CT), the region of interest was delineated, and the maximum cross section of the lesion was selected as the input image. Five convolutional neural networks (CNNs) and Vision Transformer (ViT) were used to construct a 2D DTL model. The 2D model constructed by the maximum section (n) and the upper and lower layers (n - 1, n + 1) of the lesion was used for feature extraction, and the features were selected. The remaining features were pre-fused to construct a 2.5D model. The whole lesion image was selected for input and constructing a 3D model.Results: In the 2D model, the area under curve (AUC) of Resnet50 was 0.950 in the training cohort and 0.907 in the internal validation cohort. In the 2.5D model, the AUCs of Vgg11 in the internal validation cohort and external validation cohort 1 were 0.937 and 0.965, respectively. The AUCs of Inception_v3 in the training cohort and external validation cohort 2 were 0.981 and 0.950, respectively. The AUC values of 3D_Resnet50 in the four cohorts were 0.987, 0.937, 0.938, and 0.905.Conclusions: The DTL model based on multiple different dimensions can be used as a highly sensitive and specific tool for the non-invasive differential diagnosis of thymomas and thymic cysts to assist clinicians in decision-making.","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142296456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical factors associated with high PD-L1 expression in patients with early-stage non-small cell lung cancer. 与早期非小细胞肺癌患者 PD-L1 高表达相关的临床因素。

IF 2.3 3区医学

Thoracic Cancer Pub Date : 2024-09-19 DOI: 10.1111/1759-7714.15453

Shuta Ohara, Kenichi Suda, Akira Hamada, Masato Chiba, Masaoki Ito, Masaki Shimoji, Toshiki Takemoto, Junichi Soh, Yasuhiro Tsutani

{"title":"Clinical factors associated with high PD-L1 expression in patients with early-stage non-small cell lung cancer.","authors":"Shuta Ohara, Kenichi Suda, Akira Hamada, Masato Chiba, Masaoki Ito, Masaki Shimoji, Toshiki Takemoto, Junichi Soh, Yasuhiro Tsutani","doi":"10.1111/1759-7714.15453","DOIUrl":"https://doi.org/10.1111/1759-7714.15453","url":null,"abstract":"Background: Superior outcomes have been obtained for neoadjuvant treatment with immune checkpoint inhibitors (ICI) plus chemotherapy over neoadjuvant chemotherapy alone, especially in patients with high programmed cell death ligand 1 (PD-L1) expression. However, it is not always possible to obtain sufficient tumor specimens for biomarker testing before surgery. In this study, we explored clinical factors that can predict high PD-L1 expression.Methods: We retrospectively enrolled 340 lung cancer patients who received pulmonary resection between 2014 and 2023 and who had PD-L1 expression data. Chi-squared tests and logistic regression analyses were used to identify clinical factors associated with high PD-L1 status.Results: Univariable and multivariable analyses revealed that smoking, high maximum standardized uptake value (SUVmax) of 18F-fluorodeoxyglucose positron emission computed tomography (18F-FDG PET/CT), and high plasma fibrinogen are independent predictors of high PD-L1 expression. A predictive score for high PD-L1 expression (ranging from 0 to 3) was developed based on these parameters. Notably, only 5% of patients with a score of 0 exhibited high PD-L1 expression, whereas this proportion increased to 53% for patients with a score of 3.Conclusion: These results showed that plasma fibrinogen, smoking history, and SUVmax are predictors of high PD-L1 expression, providing a basis for identifying patients expected to benefit from neoadjuvant ICI treatment.","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142296457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

miR‐30c‐5p inhibits esophageal squamous cell carcinoma progression by repressing the PI3K/AKT signaling pathway miR-30c-5p 通过抑制 PI3K/AKT 信号通路抑制食管鳞状细胞癌的进展

IF 2.9 3区医学

Thoracic Cancer Pub Date : 2024-09-18 DOI: 10.1111/1759-7714.15427

Haochun Shi, Binyang Pan, Jiaqi Liang, Benjie Cai, Gujie Wu, Yunyi Bian, Guangyao Shan, Shencheng Ren, Yiwei Huang, Weigang Guo

{"title":"miR‐30c‐5p inhibits esophageal squamous cell carcinoma progression by repressing the PI3K/AKT signaling pathway","authors":"Haochun Shi, Binyang Pan, Jiaqi Liang, Benjie Cai, Gujie Wu, Yunyi Bian, Guangyao Shan, Shencheng Ren, Yiwei Huang, Weigang Guo","doi":"10.1111/1759-7714.15427","DOIUrl":"https://doi.org/10.1111/1759-7714.15427","url":null,"abstract":"BackgroundEsophageal squamous cell carcinoma (ESCC) is one of the most common malignant tumors, with high incidence and poor prognosis. Revealing mechanisms of ESCC progression and developing new therapeutic targets remains crucial. The aim of this study was to elucidate the molecular mechanism of miR‐30c‐5p in regulating the malignant progression of ESCC.MethodsTCGA, GEO, and other datasets were used to analyze the differential expression of miR‐30c‐5p in ESCC and adjacent tissues, and its impact on prognosis. Then the effects of miR‐30c‐5p on the proliferation, migration, and invasion of TE‐1 and Eca9706 cells were investigated through proliferation experiments, transwell and wounding healing assays. The regulatory mechanism of miR‐30c‐5p on the PI3K/AKT signaling pathway and its interaction in cancer progression were investigated through Western blots, dual‐luciferase reporter assay, and rescue experiments.ResultsmiR‐30c‐5p was significantly downregulated in ESCC tissue and represented a poor prognosis. miR‐30c‐5p mimic significantly inhibited the proliferation, migration, and invasion ability of ESCC, while miR‐30c‐5p inhibitor significantly promoted tumor cell progression. Through bioinformatic analysis and experimental results, miR‐30c‐5p interacted directly with PIK3CA mRNA and inhibited subsequent signaling pathway activation. PIK3CA activator could eliminate the inhibitory effects of miR‐30c‐5p mimic on the progression of ESCC, while PIK3CA inhibitors could rescue the promoting effect of miR‐30c‐5p inhibitor group cells.ConclusionsIn summary, we found that miR‐30c‐5p inhibited the proliferation, invasion and migration of ESCC by inhibiting PI3K/AKT signaling pathway for the first time, and this study is expected to provide a novel insight and potential therapeutic target for managing ESCC.","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142257028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Subxiphoid video-assisted thoracoscopic extend thymectomy with sternal suspension for thymoma. 剑突下视频辅助胸腔镜扩展胸腺切除术，胸骨悬吊治疗胸腺瘤。

IF 2.3 3区医学

Thoracic Cancer Pub Date : 2024-09-15 DOI: 10.1111/1759-7714.15449

Bin Jia, Chen Chen, Ting Gong, Zhenfa Zhang, Bingsheng Sun

{"title":"Subxiphoid video-assisted thoracoscopic extend thymectomy with sternal suspension for thymoma.","authors":"Bin Jia, Chen Chen, Ting Gong, Zhenfa Zhang, Bingsheng Sun","doi":"10.1111/1759-7714.15449","DOIUrl":"https://doi.org/10.1111/1759-7714.15449","url":null,"abstract":"Background: Thymoma is a primary tumor of the thymus, commonly located in the anterior mediastinum. Most thymomas are benign or low-grade malignant, but they can invade surrounding organs or metastasize. The primary treatment for thymoma is surgical resection. Traditional methods involve open thoracotomy, but it is traumatic, with slow recovery and many complications. In recent years, with the development of thoracoscopic techniques, thoracoscopic total thymectomy has gradually become the preferred method for small size thymomas due to its minimally invasive, safe, and effective.Methods: This paper introduces a thoracoscopic extend thymectomy technique, the subxiphoid video-assisted thoracoscopic extend thymectomy with sternal suspension. This method involves placing hooks at the upper and lower ends of the sternum to suspend the sternum upward, increasing the thoracic cavity space and facilitating thoracoscopic operations. This research reviews the clinical data of 59 patients with early-stage thymomas treated with this technique at our center since 2020 and analyzes the perioperative therapeutic efficacy and safety. It also compares the outcomes with those of 17 patients who underwent thoracoscopic approaches.Results: The results show that subxiphoid video-assisted thoracoscopic total thymectomy with sternal suspension is an innovative and effective surgical method, achieving the same tumor eradication as other thoracic surgeries. The flexible switching of observation ports provides a more comprehensive surgical field, reduces surgical trauma and complications, and improves the surgical outcomes and quality of life for patients.","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142296468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Subdivision of M1 category and prognostic stage for de novo metastatic breast cancer to enhance prognostic prediction and guide the selection of locoregional therapy. 细分新发转移性乳腺癌的 M1 类别和预后分期，以加强预后预测并指导局部治疗的选择。

IF 2.3 3区医学

Thoracic Cancer Pub Date : 2024-09-15 DOI: 10.1111/1759-7714.15452

Lei Ji, Ge Song, Min Xiao, Xi Chen, Qing Li, Jiayu Wang, Ying Fan, Yang Luo, Qiao Li, Shanshan Chen, Fei Ma, Binghe Xu, Pin Zhang

{"title":"Subdivision of M1 category and prognostic stage for de novo metastatic breast cancer to enhance prognostic prediction and guide the selection of locoregional therapy.","authors":"Lei Ji, Ge Song, Min Xiao, Xi Chen, Qing Li, Jiayu Wang, Ying Fan, Yang Luo, Qiao Li, Shanshan Chen, Fei Ma, Binghe Xu, Pin Zhang","doi":"10.1111/1759-7714.15452","DOIUrl":"https://doi.org/10.1111/1759-7714.15452","url":null,"abstract":"Background: Although de novo metastatic breast cancer (dnMBC) is acknowledged as a heterogeneous disease, the current staging systems do not distinguish between patients within the M1 or stage IV category. This study aimed to refine the M1 category and prognostic staging for dnMBC to enhance prognosis prediction and guide the choice of locoregional treatment.Methods: We selected patients with dnMBC from the SEER database (2010-2019), grouping them into training (N = 8048) and internal validation (N = 3450) cohorts randomly at a 7:3 ratio. An independent external validation cohort (N = 660) was enrolled from dnMBC patients (2010-2023) treated in three hospitals. Nomogram-based risk stratification was employed to refine the M1 category and prognostic stage, incorporating T/N stage, histologic grade, subtypes, and the location and number of metastatic sites. Both internal and external validation sets were used for validation analyses.Results: Brain, liver, or lung involvement and multiple metastases were independent prognostic factors for overall survival (OS). The nomogram-based stratification effectively divided M1 stage into three groups: M1a (bone-only involvement), M1b (liver or lung involvement only, with or without bone metastases), and M1c (brain metastasis or involvement of both liver and lung, regardless of other metastatic sites). Only subtype and M1 stage were included to define the final prognostic stage. Significant differences in OS were observed across M1 and prognostic subgroups. Patients with the M1c stage benefited less from primary tumor surgery in comparison with M1a stage.Conclusion: Subdivision of the M1 and prognostic stage could serve as a supplement to the current staging guidelines for dnMBC and guide locoregional treatment.","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142296459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Proton therapy for breast cancer: Reducing toxicity 质子治疗乳腺癌：减少毒性

IF 2.9 3区医学

Thoracic Cancer Pub Date : 2024-09-14 DOI: 10.1111/1759-7714.15451

Kailin Qiao, Yuchun Wei, Cheng Tao, Jian Zhu, Shuanghu Yuan

引用次数: 0

Cytomegalovirus tracheobronchitis mimicking lung cancer progression in a patient with lung adenocarcinoma: A case report 一名肺腺癌患者模拟肺癌进展的巨细胞病毒气管支气管炎：病例报告

IF 2.9 3区医学

Thoracic Cancer Pub Date : 2024-09-14 DOI: 10.1111/1759-7714.15446

Green Hong, Sung Joon Han, Kyung‐Hee Kim, Dongil Park, Chaeuk Chung

引用次数: 0

Left pulmonary vein anatomical variation in Turner syndrome. Benefits of three‐dimensional visualization for surgical planning 特纳综合征的左肺静脉解剖变异。三维可视化对手术规划的益处

IF 2.9 3区医学

Thoracic Cancer Pub Date : 2024-09-11 DOI: 10.1111/1759-7714.15422

Gabrielle Drevet, Valentin Soldea, François Tronc

引用次数: 0